A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
for Relapsed Refractory Multiple Myeloma
48 locations incl. Gilbert
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT07391657·Phase 3·Recruiting